Human EGFR antibody

Epidermal growth factor receptor, ERBB, ERBB1, HER1, NISBD2, PIG61, mENA, ERRP, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian)

EGFR, ATGA0197-10 µg, ATGA0197-20 µg, ATGA0197-50 µg, ATGA0197-100 µg, ATGA0197-250 µg, ATGA0197-500 µg, ATGA0197-1 mg, ATGA0197-10, ATGA0197-20, ATGA0197-50, ATGA0197-100, ATGA0197-250, ATGA0197-500, ATGA0197-1

Cohen S, (1964) Nat Cancer Inst Monogr, 13: 13-27.; ; Toyoda H, et al. (1995) J Biol Chem, 270: 7495-500.; ; Carpenter G, et al. (1978) Nature,276: 409-10.

Tran AV, et al. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers. (Acta Biomater. 2018) {https://pubmed.ncbi.nlm.nih.gov/29775731/}; ; Tran VA, et al. Multimodal Mesoporous Silica Nanocarriers for Dual Stimuli-Responsive Drug Release and Excellent Photothermal Ablation of Cancer Cells. (Int J Nanomedicine. 2020) {https://pubmed.ncbi.nlm.nih.gov/33116494/}; ; Mohamed Isa ED, et al. Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment. (Pharmaceutics. 2021) {https://pubmed.ncbi.nlm.nih.gov/33498885/}

The antibody has been tested by ELISA, Western blot and ICC/IF analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

The cell lysate (40ug) was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human EGFR antibody (1:1000) . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.; ; Lane .: A431 cell lysate;

ICC/IF analysis of EGFR in HeLa cells. The cell was stained with ATGA0197 (1:100) . The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue) .